From GlobeNewswire: 2025-06-04 09:20:00

The Overactive Bladder Treatment Market was estimated at USD 3.63 billion in 2023, projected to reach USD 5.45 billion by 2032, with a CAGR of 4.64%. Factors driving growth include increasing conditions associated with OAB, aging populations, improved diagnosis levels, and innovative pharmaceutical treatments. The U.S. market alone was estimated at USD 1.05 billion in 2023, with a projected growth to USD 1.56 billion by 2032, driven by high incidence rates, developed healthcare infrastructure, and increased treatment adoption.

The Mirabegron segment led the market in 2023, holding a 26% market share due to its potency and safety profile. Idiopathic OAB accounted for 76% of the market share, driven by its high prevalence and mysterious etiology. Retail pharmacies dominated the market in 2023 with a 76% share due to their accessibility and direct patient reach.

North America leads the Overactive Bladder Treatment Market, with a 37% market share in 2023, while Asia Pacific is expected to show the fastest growth due to increasing healthcare spending, awareness, and geriatric population. SNS Insider is a leading market research and consulting agency providing clients with the knowledge they need to navigate changing market conditions.



Read more at GlobeNewswire: Overactive Bladder Treatment Market to Reach USD 5.45